| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Obesity and diabetes have been reported to increase the risk for endometrial carcinoma. On the analysis of the endocrine profiles in these patients, we focused our attention on the existence of patients with high serum prolactin (PRL) levels. We investigated the contribution of PRL to the endometrial carcinogenesis. Although the patients with hyperprolactinemia presented the same characteristics as those of endometrial carcinoma, PTEN mutations were detected in a small proportion. PRL might be involved in endometrial carcinogenesis via another molecular alteration.
We investigated the endocrinological contribution to the enhanced response to MPA in endometrial cancer. In MPA treatment for early endometrial cancer, improvement of IR and hyperprolactinemia can be expected to result in favorable outcomes.
|
